1. Home
  2. BDSX vs ENTX Comparison

BDSX vs ENTX Comparison

Compare BDSX & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • ENTX
  • Stock Information
  • Founded
  • BDSX 2005
  • ENTX 2010
  • Country
  • BDSX United States
  • ENTX Israel
  • Employees
  • BDSX N/A
  • ENTX N/A
  • Industry
  • BDSX Precision Instruments
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BDSX Health Care
  • ENTX Health Care
  • Exchange
  • BDSX Nasdaq
  • ENTX Nasdaq
  • Market Cap
  • BDSX 115.4M
  • ENTX 104.0M
  • IPO Year
  • BDSX 2020
  • ENTX 2018
  • Fundamental
  • Price
  • BDSX $0.45
  • ENTX $1.86
  • Analyst Decision
  • BDSX Strong Buy
  • ENTX Strong Buy
  • Analyst Count
  • BDSX 5
  • ENTX 1
  • Target Price
  • BDSX $1.75
  • ENTX $10.00
  • AVG Volume (30 Days)
  • BDSX 1.1M
  • ENTX 40.5K
  • Earning Date
  • BDSX 08-07-2025
  • ENTX 08-08-2025
  • Dividend Yield
  • BDSX N/A
  • ENTX N/A
  • EPS Growth
  • BDSX N/A
  • ENTX N/A
  • EPS
  • BDSX N/A
  • ENTX N/A
  • Revenue
  • BDSX $74,463,000.00
  • ENTX $223,000.00
  • Revenue This Year
  • BDSX $17.29
  • ENTX N/A
  • Revenue Next Year
  • BDSX $29.33
  • ENTX N/A
  • P/E Ratio
  • BDSX N/A
  • ENTX N/A
  • Revenue Growth
  • BDSX 35.76
  • ENTX N/A
  • 52 Week Low
  • BDSX $0.17
  • ENTX $1.41
  • 52 Week High
  • BDSX $2.04
  • ENTX $2.79
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 75.72
  • ENTX 44.39
  • Support Level
  • BDSX $0.29
  • ENTX $1.91
  • Resistance Level
  • BDSX $0.44
  • ENTX $2.04
  • Average True Range (ATR)
  • BDSX 0.03
  • ENTX 0.10
  • MACD
  • BDSX 0.02
  • ENTX 0.00
  • Stochastic Oscillator
  • BDSX 98.04
  • ENTX 37.84

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: